ALLR 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• On July 7, we announced the Clinical Laboratory Improvement Amendments (CLIA) certification for our in-house laboratory. With all equipment in place, our Horsholm, Denmark, laboratory is able to do all necessary testing in house to support the acceleration of stenoparib toward FDA registration. With…

• Research and development expenses decreased $1.0 million primarily due to reduced costs and supplies of the Phase II clinical trial of stenoparib. A significant amount of these fees occurred in 2025 and were recognized at the time of purchase.

• General and administrative expenses decreased by $0.7 million for the six months ended June 30, 2026, compared to June 30, 2025. The decrease was primarily due to a reduction in legal fees.

• For the three months ended June 30, 2026, net other income decreased $2.5 million from the comparable quarter. Interest income was substantially consistent. Foreign exchange gains decreased $1.7 million (moving from a $1.6 million gain in Q2 2025 to a $0.1 million loss in Q2 2026). Interest expense …

• For the six months ended June 30, 2026, net other income decreased $2.9 million from the comparable period. Foreign exchange decreased $1.8 million while interest expense and derivative liability increased $1 million with the March promissory note.

相对上期删除的文字 · 来源:10-Q · 2026-05-15

• On March 3, 2025, the board of directors approved a share repurchase program, with authorization to purchase up to $5 million of the Company’s outstanding shares of common stock over a twelve month period. On February 26, 2026, the board of directors approved a new share repurchase program, with aut…

• On April 27, 2026, the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company’s DRP® companion diagnostic specific to stenoparib.

• For the three months ended March 31, 2026, compared to March 31, 2025

• For the three months ended March 31, 2026, compared to March 31, 2025

• For the three months ended March 31, 2026, net other income decreased $0.4 million from the comparable quarter. Interest income and foreign exchange decreased $0.1 million each while interest expense increased $0.2 million.

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• Sales of our common stock under our equity line of credit with Tumim Stone Capital LLC may result in substantial dilution to our stockholders, may adversely affect the market price of our common stock and may not provide us with the full amount of capital contemplated by the facility.

• On January 28, 2026, we entered into a Common Stock Purchase Agreement with Tumim Stone Capital LLC, or Tumim, under which we have the right, but not the obligation, to direct Tumim to purchase up to $6.0 million of newly issued shares of our common stock, subject to the conditions and limitations c…

• Any issuances under the facility will dilute the ownership and voting interests of our existing stockholders. Tumim may resell shares it acquires into the public market, and such sales, or the perception that such sales may occur, could cause or contribute to a decline in the market price of our com…

• Our obligations under the Streeterville financing may materially impair our liquidity and financing flexibility, and a trigger event or default could result in acceleration, increased amounts owed, enforcement against restricted cash, pledged equity and subsidiary guarantors, and dilution to our sto…

• On March 2, 2026, we entered into a Note Purchase Agreement with Streeterville Capital, LLC, or Streeterville, under which we issued an A-1 Note and a B Note for aggregate gross proceeds of $20.0 million. The A-1 Note had an initial stated principal amount of approximately $10.93 million, including …